论文部分内容阅读
目的:了解血清髓过氧化物酶和超敏C反应蛋白在冠心病中的应用价值。方法:采用酶联免疫吸附试验(ELISA)测定MPO水平;用美国贝克曼Array 360全自动特种蛋白分析仪,以速率散射比浊法测定hs-CRP水平。结果:对73例冠心病患者及30例对照组检测发现,不同病变组MPO水平与hs-CRP水平均高于对照组(P<0.05)。MPO与hs-CRP水平,对照组(n=30)分别为5.37±0.71 U/ml,3.84±0.59 mg/L;单支病变组(28例)分别为:7.54±01.35 U/ml,13.59±3.02 mg/L;双支病变组(24例)分别为:8.91±2.12 U/ml,15.45±3.16 mg/L;三支病变组(21例)分别为:10.06±2.06 U/ml,17.06±3.31 mg/L。各病变组间比较(P<0.05)。MPO与hs-CRP水平呈弱相关(r=0.31,P=0.048)。结论:冠状动脉病变越广泛越严重,血清MPO与hs-CRP水平越高。MPO的升高可作为冠状动脉疾病的一个危险因子,可用于冠心病的风险评估。
Objective: To investigate the value of serum myeloperoxidase and high sensitive C-reactive protein in coronary heart disease. Methods: The level of MPO was determined by enzyme-linked immunosorbent assay (ELISA). The hs-CRP level was determined by rate nephelometry with the Beckman Array 360 automatic special protein analyzer. Results: The results of 73 patients with CHD and 30 controls showed that MPO and hs-CRP in different pathological changes were higher than those in control group (P <0.05). The levels of MPO and hs-CRP were 5.37 ± 0.71 U / ml and 3.84 ± 0.59 mg / L respectively in the control group (n = 30) and 7.54 ± 0.01.35 U / ml in the single vessel disease group (n = 30) 3.02 mg / L, and double-vessel lesion group (24 cases) were 8.91 ± 2.12 U / ml and 15.45 ± 3.16 mg / L respectively. The three lesion groups (21 cases) were 10.06 ± 2.06 U / ml and 17.06 ± 3.31 mg / L. Each lesion was compared (P <0.05). MPO and hs-CRP levels were weakly correlated (r = 0.31, P = 0.048). Conclusion: The more extensive and severe coronary artery disease, the higher the level of serum MPO and hs-CRP. Elevated MPO can be used as a risk factor for coronary artery disease and can be used for risk assessment of coronary heart disease.